A breakthrough large-scale production platform has been unveiled by researchers at Allife Medicine and Peking University for generating consistent, high-quality extracellular vesicles (EVs) from induced mesenchymal stem cells (iMSCs). Overcoming challenges like limited expansion capacity, phenotypic variations, and batch inconsistencies in current MSC-EV manufacturing processes, this innovative platform ensures homogeneous EV production at clinical trial-relevant scales.
The innovative methodology, outlined in a recent publication by lead author Shixin Gong and a team of researchers, leverages a microcarrier suspension bioreactor culture system to cultivate and amplify MSCs derived from extended pluripotent stem cells (EPSCs). This approach yields a dense, replenishable, dependable, and phenotypically stable cell source, maintaining the MSC characteristics consistently during expansion.
Integration of a fixed-bed bioreactor into the system enables automated continuous expansion and downstream collection of induced MSCs (iMSCs). The resulting EVs closely resemble those obtained from primary MSCs in terms of size distribution, morphology, and expression of EV-specific markers.
The EVs produced through fixed-bed culture exhibit uniform cell distribution, minimal aggregation, and consistently high viability across the matrix, remaining stable for up to two months when stored at -80°C. Safety assessments in male mice 13 days post-administration suggest that these EVs are as safe as those derived from primary MSCs, showing no significant cytokine expression and indicating normal liver function, tissue integrity, and body weight.
Encouraging results from therapeutic efficacy studies in a mouse model of bleomycin-induced pulmonary fibrosis demonstrate notable health improvements and reduced disease severity following treatment with iMSC-derived EVs. The researchers highlight the potential of mass-producing standardized iMSC populations with enhanced reproducibility and consistency compared to primary MSCs, paving the way for tailored EV production and large-scale clinical-grade manufacturing.
Addressing the challenges of industrial deployment of fixed beds, the team implemented strategies such as an external recirculation loop with inline heat exchange, low-shear perfusion, and distributed temperature probes for verifying uniformity. The optimized approach achieved a remarkable daily production rate of 1.2×10^13 particles per fixed-bed bioreactor, translating to 12 to 120 clinical doses per day and enhancing the clinical feasibility of large-scale iMSC-EV manufacturing.
The integration of fixed-bed bioreactors for extensive manufacturing not only boosts clinical applicability but also sets the stage for the next wave of cell-free regenerative therapies, as emphasized by the research team’s concluding remarks. This cutting-edge platform holds promise for revolutionizing EV production and advancing the field of regenerative medicine towards scalable, standardized, and clinically relevant applications.
- The platform developed by Allife Medicine and Peking University offers a scalable and standardized approach for producing high-quality extracellular vesicles (EVs) from induced mesenchymal stem cells (iMSCs).
- The use of a microcarrier suspension bioreactor culture system ensures consistent expansion of MSCs derived from extended pluripotent stem cells (EPSCs), maintaining phenotypic stability throughout the process.
- Integration of a fixed-bed bioreactor enables automated continuous expansion and downstream harvesting of induced MSCs, resulting in EVs comparable to those derived from primary MSCs in terms of size, morphology, and marker expression.
- The optimized production platform demonstrates high viability and stability of EVs over storage, with safety assessments in mice supporting the safety profile of iMSC-derived EVs.
Tags: downstream, bioreactor, extracellular vesicles, biotech
Read more on genengnews.com
